NEW YORK CITY, NY / ACCESS Newswire / February 4, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims ...

Sage Therapeutics (SAGE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Sage Therapeutics rejects Biogen deal offer; Silvus Technologies considers sale/IPO; Allakos downsizes; MrBeast bids on ...

NEW YORK CITY, NY / ACCESS Newswire / January 31, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of ...

Get Our Latest Analysis on SAGE Sage Therapeutics Stock Down 1.4 % SAGE opened at $7.25 on Friday. The firm has a market cap of $443.48 million, a P/E ratio of -1.30 and a beta of 0.91. Sage ...

Learn more about whether Biogen Inc. or Gilead Sciences, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Because this plan is a short plan based on a test of resistance it is referred to as a Short Resistance Plan. Check the time stamp on this data. Updated AI-Generated Signals for Sage Therapeutics Inc.

Enhance your stock picks with dividend metrics like per-share dividends, yield, frequency, payout ratios, and more.

Short interest is currently not available. Nasdaq provides information of company’s short interest and the average days it takes to cover them. Short interest and days to cover can be used to ...